© 2003 by Oxford University Press
© 2003 Oxford University Press
ARTICLE |
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Affiliations of authors: M. Schön, A. B. Bong, C. Drewniok, J. Herz, H. Gollnick, M. P. Schön, Department of Dermatology, Otto-von-Guericke-University, Magdeburg, Germany; C. C. Geilen, Department of Dermatology, University Medical Center "Benjamin Franklin," Berlin, Germany; J. Reifenberger, Department of Dermatology, Heinrich-Heine-University, Düsseldorf, Germany; B. Benninghoff, 3M Medica, Pharmaceutical Research, Neuss, Germany; H. B. Slade, 3M Pharmaceuticals, St. Paul, MN.
Correspondence to: Michael P. Schön, MD, or Margarete Schön, PhD, Rudolf-Virchow-Center for Biomedical Research and Department of Dermatology and Venereology, Julius-Maximilians-University, Versbacher Str. 9, 97078 Würzburg, Germany (e-mail: Michael.Schoen{at}Medizin.Uni-Magdeburg.de or schoenmargret{at}web.de).
Background: The incidence of nonmelanoma skin cancer, basal cell carcinomas (BCCs), and squamous cell carcinomas (SCCs) is increasing, representing a major medical and economic problem. Imiquimod, a topical small-molecule immune response modifier, has shown efficacy toward BCC and actinic keratoses in clinical trials. Imiquimod acts both indirectly, via cytokine-mediated stimulation of cellular immune responses, and directly, through unknown mechanisms against tumor cells. We examined the mechanism by which imiquimod induces apoptosis in cancer cells. Methods: Apoptosis was assessed by enzyme-linked immunosorbent assay, western blot analysis, and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays in five SCC cell lines, HaCaT cells (a spontaneously immortalized human keratinocyte cell line), and normal keratinocytes treated with imiquimod, with its analog resiquimod, or with neither. Expression of death receptors, caspases, and cytochrome c in the apoptotic signaling cascade was analyzed using western blot and flow cytometric analyses. The functional relevance of imiquimod-induced cytochrome c release was assessed by transfection of HaCaT cells with Bcl-2. Apoptosis in BCCs in vivo was assessed by TUNEL assays of imiquimod-treated and untreated tumors from three patients. Differences between treated and untreated cells and tumors were determined using a two-tailed Student’s t test. Results: Imiquimod, but not resiquimod, induced apoptosis in all SCC cell lines and HaCaT cells. This induction involved activation of several caspases and Bcl-2–dependent cytosolic translocation of cytochrome c but was independent of the membrane-bound death receptors Fas, tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-R1–R4 receptors, and tumor necrosis factor-R1 and -R2 receptors. Topical application of imiquimod to BCC tumors in vivo induced apoptosis. Conclusion: Imiquimod has the potential to induce apoptosis in skin cancer cells, possibly by circumventing mechanisms developed by malignant tumors to resist apoptotic signals.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. A. Clark, S. J. Huang, G. F. Murphy, I. G. Mollet, D. Hijnen, M. Muthukuru, C. F. Schanbacher, V. Edwards, D. M. Miller, J. E. Kim, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells J. Exp. Med., September 29, 2008; 205(10): 2221 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Zagon, R. N. Donahue, M. Rogosnitzky, and P. J. Mclaughlin Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function Experimental Biology and Medicine, August 1, 2008; 233(8): 968 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. J. M. Smits, P. Ponsaerts, Z. N. Berneman, and V. F. I. Van Tendeloo The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy Oncologist, August 1, 2008; 13(8): 859 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schon, B. G. Wienrich, S. Kneitz, H. Sennefelder, K. Amschler, V. Vohringer, O. Weber, T. Stiewe, K. Ziegelbauer, and M. P. Schon KINK-1, a Novel Small-Molecule Inhibitor of IKK{beta}, and the Susceptibility of Melanoma Cells to Antitumoral Treatment J Natl Cancer Inst, June 18, 2008; 100(12): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Moarbess, H. El-Hajj, Y. Kfoury, M. E. El-Sabban, Y. Lepelletier, O. Hermine, C. Deleuze-Masquefa, P.-A. Bonnet, and A. Bazarbachi EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma Blood, April 1, 2008; 111(7): 3770 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stary, C. Bangert, M. Tauber, R. Strohal, T. Kopp, and G. Stingl Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells J. Exp. Med., June 11, 2007; 204(6): 1441 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Inglefield, C. J. Larson, S. J. Gibson, H. Lebrec, and R. L. Miller Apoptotic Responses in Squamous Carcinoma and Epithelial Cells to Small-Molecule Toll-like Receptor Agonists Evaluated with Automated Cytometry J Biomol Screen, September 1, 2006; 11(6): 575 - 585. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Brown, C. L. Atkins, L. Ghali, R. Cerio, C. A. Harwood, and C. M. Proby Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-blind, Placebo-Controlled Trial Arch Dermatol, August 1, 2005; 141(8): 985 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. Wolf, L. Cerroni, K. Kodama, and H. Kerl Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod Arch Dermatol, April 1, 2005; 141(4): 510 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Eidsmo, S. Nylen, A. Khamesipour, M.-A. Hedblad, F. Chiodi, and H. Akuffo The Contribution of the Fas/FasL Apoptotic Pathway in Ulcer Formation during Leishmania major-Induced Cutaneous Leishmaniasis Am. J. Pathol., April 1, 2005; 166(4): 1099 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gilliet, C. Conrad, M. Geiges, A. Cozzio, W. Thurlimann, G. Burg, F. O. Nestle, and R. Dummer Psoriasis Triggered by Toll-like Receptor 7 Agonist Imiquimod in the Presence of Dermal Plasmacytoid Dendritic Cell Precursors Arch Dermatol, December 1, 2004; 140(12): 1490 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Stockfleth, E. Christophers, B. Benninghoff, and W. Sterry Low Incidence of New Actinic Keratoses After Topical 5% Imiquimod Cream Treatment: A Long-term Follow-up Study Arch Dermatol, December 1, 2004; 140(12): 1542 - 1542. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Urosevic, P. A. Oberholzer, T. Maier, J. Hafner, E. Laine, H. Slade, B. Benninghoff, G. Burg, and R. Dummer Imiquimod Treatment Induces Expression of Opioid Growth Factor Receptor: A Novel Tumor Antigen Induced by Interferon-{alpha}? Clin. Cancer Res., August 1, 2004; 10(15): 4959 - 4970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Death by the Imiqui-MOD Squad Journal Watch Dermatology, September 9, 2003; 2003(909): 3 - 3. [Full Text]
|
|